GH axis
8GH pulses, IGF-1 and pituitary-support claims.
What does it do?
Modified GRF(1–29), often called CJC-1295 without DAC, is a short-acting GHRH analogue; DAC studies are not exact-product evidence.
Approved & studied uses
No established medical use is documented for this formulation.
Evidence limits
View research →Clinical effectiveness, pharmacokinetics, and long-term safety of the exact no-DAC product.1
1 distinct primary sources or abstracts checked. Evidence may concern a parent compound, individual blend ingredient, animal, or cell model; it does not necessarily establish a benefit for this exact product.
Evidence definitions →Key safety information
All risks →No-DAC clinical safety missing
The FDA review did not identify human clinical safety studies of the no-DAC free-base or acetate forms.1
No FDA-approved CJC-1295 product. FDA evaluates non-DAC and DAC active moieties separately.
Molecular information
Amino-acid sequence
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
Residue count only · sequence not verified1
An exact sequence has not been verified for this formulation.
Length29 amino acids
Molecular weight · Da3367.95 Da
Formula, sequence notation & identity
Molecular formulaC152H252N44O421
Modified GRF(1–29), commonly marketed as CJC-1295 without DAC; amidated GHRH analog.
FDA distinguishes this free-base/acetate peptide from DAC forms carrying an albumin-binding modification. Naming inconsistencies matter.
Pep-Pedia identity details
30 amino acids · 3,367.97 Da
Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-LysThe reference lists 29 residues, but its sequence contains 30. No exact sequence is inferred from these conflicting values.
Reference description; checked chemical identity above takes precedence when available.8
Pharmacokinetics
How long does it stay in the body?
Unverified reference estimateNot independently confirmed
Reference half-life30 min7
Route / formulationSource page: Injectable. Exact PK route not verified.
The cited Teichman study concerns CJC-1295 with DAC. It does not establish a 30-minute human half-life for the no-DAC form.
50%of reference level
Illustrative scenario using an unverified reference estimate.
About 3% remaining after 2.5 h
Five half-lives in this estimated model. This is not a prediction of when effects stop.
Evidence and model details
Population: Not established by the reference estimate
Source’s stated attribution: Teichman et al. 2006
Source’s reported peak time: 15 min. This has not been independently confirmed and is not used in the elimination curve.
100 × 2−time / half-life. Time zero is a reference level, not the moment of administration. Absorption, repeated dosing, metabolites and clinical effects are not modeled. Five half-lives leaves 3.125%, not zero. This curve cannot determine a dosing interval.
What to expect
Study outcomes
Reported timelines
Reference & communityDays 1–7 / weeks 2–4 / 4–8 / 8–12 / 12+
Reference/community sequence: sleep/dreams; recovery; skin/composition; lean mass/joints; continuing gains. No validated timeline or non-desensitization guarantee.8
These are reported timelines, not a prediction of your response.
Community poll 10 topics · Pep-Pedia snapshot
Voluntary, unverified reports. These percentages do not measure effectiveness or safety.
Experience
The source hides 1 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Duration of use
Number of responses to this question: not disclosed.
Age range
The source hides 2 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Gender
Number of responses to this question: not disclosed.
Primary goal
The source hides 2 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Effectiveness
The source hides 2 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Side effects
The source hides 7 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Dosage frequency
Number of responses to this question: not disclosed.
Would recommend
Number of responses to this question: not disclosed.
How discovered
The source hides 2 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Source & limitations
The source displays “569 responses” for this profile. This is not a confirmed participant count or a denominator for individual questions.
- Voluntary self-reports from Pep-Pedia visitors; identity, treatment, outcomes and timing are unverified. These data are not efficacy or safety estimates.
- The source displays a profile-wide response label, not a confirmed unique participant count. It stays unchanged across questions. Question-specific denominators and absolute option counts are not exposed.
- Only the top five categories are displayed for some questions. Extra categories are retained as an undisplayed-category count; their labels and percentages are unavailable.
- Displayed percentages are rounded. They may not total 100%, especially where categories are hidden.
- This is a dated snapshot, not a live survey or current recommendation.
Protocols
Doses & schedules
Compare purpose, amount, route, frequency, and duration.
Scroll to compare all columns →
| Route | Dose | Frequency | Goal / evidence | Duration | References |
|---|---|---|---|---|---|
| SubQ | 100 mcg | 2x daily (morning and bedtime) | Anti-Aging/WellnessReference report | 12-16 weeks continuous use | 8 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source tabs Injectable | |||||
| SubQ | 100-150 mcg | 3x daily (morning, post-workout, bedtime) | Body CompositionReference report | 12-16 weeks continuous use | 8 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source tabs Injectable | |||||
| SubQ | 200 mcg | 2-3x daily with GHRP | Maximum GH ReleaseReference report | 12-16 weeks continuous use | 8 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source tabs Injectable | |||||
| SubQ | 100-200 mcg | Once at bedtime | Sleep EnhancementReference report | 12-16 weeks continuous use | 8 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source tabs Injectable | |||||
No protocols match these filters.
Study and label doses retain their study context. Reference reports are unvalidated practices, not personal treatment instructions. Ranges remain ranges; escalation stages are labeled.
Reported use periods and breaks. These do not establish a safe cycle or prove that breaks prevent tolerance.
Injectable
- Use period
- 12-16 weeks continuous use
- Break
- Optional 2-4 week breaks to assess baseline
Reported timing
Morning (upon waking), post-workout (if applicable), 30 minutes before bed
Side effects & safety
No-DAC clinical safety missing
The FDA review did not identify human clinical safety studies of the no-DAC free-base or acetate forms.
1Identity and purity uncertainty
FDA highlights inconsistent naming and insufficient physicochemical characterization across CJC forms.
1DAC evidence is different
Adverse effects reported with DAC or unspecified CJC products cannot be assigned a reliable incidence for no-DAC material.
1Symptoms
Flushing/warmth, joint pain, hand tingling, persistent edema, headache/vision change, severe fatigue or allergy need assessment.
Conditions
Reference cautions about glucose disorders, cancer, retinopathy and severe kidney disease; efficacy/safety remain unestablished.
Not a complete safety screen. Discuss health decisions with a qualified clinician.
Combinations & interactions
8 entriesCheck cautions and reported pairings. A compatibility claim does not establish that a combination is safe.
Hexarelin
Caution reportedExcess GH concern.8
Reference report · Pep-Pedia label: Monitor CombinationCJC-1295 with DAC
Avoidance reportedDuplicate GHRH exposure.8
Reference report · Pep-Pedia label: Avoid CombinationTesamorelin
Caution reportedShared receptor activity.8
Reference report · Pep-Pedia label: Use CautionIpamorelin
Unverified pairingDual receptor pathways.8
Reference report · Pep-Pedia label: SynergisticGHRP-6
Unverified pairingDual receptor pathways.8
Reference report · Pep-Pedia label: SynergisticGHRP-2
Unverified pairingDual receptor pathways.8
Reference report · Pep-Pedia label: SynergisticMK-677
Unverified pairingGH-axis overlap remains.8
Reference report · Pep-Pedia label: CompatibleGHRPs or other GH-axis peptides
Not establishedReported combinations do not supply no-DAC human interaction data. The FDA review cannot establish their clinical safety or added benefit.21
Research contextNo matching interactions. Try another name or filter.
Reconstitution calculator
Enter your peptide amount and container size. Get a volume and a simple measurement scale.
Suggested final volume mL
Estimated water to add≈ mL
For dry powder, assuming negligible volume displacement. Use bacteriostatic water only if the formulation specifies it.
1 pen unit (one dial step)=
Amounts below are total blend mass. Ingredient amounts are listed separately.
| Pen units | Amount | Volume |
|---|
Ingredients per unit
Other simple scales
Convert a specific amount
Enter an amount to calculate its volume and device setting.
Calculation & assumptions
The suggestion favors a simple 1, 2, or 5 × power-of-ten amount per unit, then the largest final volume that fits. It does not choose a dose or a biologically suitable concentration.
The water estimate applies only to dry powder and assumes negligible powder displacement. Final solution volume, specified diluent, solubility, stability, sterility, cartridge compatibility, and working fill limits must be established separately. No allowance is made for priming or transfer losses.
V2 measurement specification ↗Bacteriostatic water: formulation instructions ↗Reconstitution
FDA raises formulation and characterization questions for the no-DAC forms.1
Solubility depends on form
FDA describes limited water solubility for the free base and uncertainty about a proposed 2 mg/mL solution. An acetate powder cannot be assumed equivalent.1
No universal recipe
The review does not validate a bacteriostatic-water volume, stability period or human preparation method for a research vial.1
Reference preparation details
Reported handling information, not a validated formulation or instruction to prepare an injectable product.
Injectable
Pep-Pedia describes preparation for this route; product-specific stability has not been independently verified.
- Solvents mentioned
- Bacteriostatic water
- Reported parameters
- Source temperature: 2-8°C.
The source describes gentle mixing and avoiding vigorous shaking.
Appearance & documentation
Appearance and a purity certificate cannot establish sterility, identity, or suitability for injection.
Reported appearanceLegitimate source with COAReported appearanceProper cold chain shippingReported appearanceVacuum-sealed vialsReported variationCheck expiration datesReported concernPre-mixed solutionsReported concernDiscolored powder
8Vial sizes
Packaging examples, not a market survey. Approved and research products are not interchangeable.
Storage after mixing
Reconstituted research vials
Pep-Pedia reports these handling limits after mixing. They are not validated stability or sterility limits for your vial.
Full storage notes from Pep-Pedia
8Refrigerate immediately, use within 30 days of reconstitution
Storage depends on the formulation, diluent, container, and handling. Follow the specific product label or pharmacist’s instructions.
Pen & syringe measurements Scales, capacity & references
Pen & syringe measurements
Device units measure volume. Concentration determines the amount in mg.
1 notch = 0.01 mL
Documented 1-unit V2 models
- One dial increment
- 1 unit
- Cartridge capacity
- 3 mL
- Maximum setting
- 60 units · 0.60 mL
Use the numbered dose window. Whole-unit settings only; confirm the specification for your exact model.
1 unit = 0.01 mL
100 units = 1 mL
- 10 units
- 0.10 mL
- 30-unit capacity
- 0.30 mL
- 50 / 100-unit capacity
- 0.50 / 1 mL
Read the printed unit scale. A small line may represent 0.5, 1, or 2 units depending on the syringe.
Use the mL scale
mL syringes and calibrated pipettes
- 0.01 mL
- 10 µL
- 0.10 mL
- 100 µL
- Amount
- mL × mg/mL
Drops, sprays and other pen clicks need their own verified volume per increment. They have no universal conversion.
3 mL is cartridge capacity. It does not mean you must prepare or load 3 mL. The original vial and the pen cartridge are different containers. This reference compares measurement scales; it does not establish product or route compatibility.
Device references
AVERON V2 specifications ↗SilverLeaf V2 unit reference ↗FDA: syringe unit conversions ↗Specifications checked October 12, 2026.Research findings
No human data verifiedCompound identity & other names
Research catalogs use 'CJC-1295 no DAC' for a modified GHRH fragment. Human findings for long-acting CJC-1295 with DAC should not be transferred to this material; direct human evidence for the no-DAC forms is a major gap.
Other names: Mod GRF 1-29 · Modified GRF(1-29) · CJC-1295 without DAC · CJC1295 · tetrasubstituted GRF · CJC-1295 (without DAC)
No FDA-approved CJC-1295 product. FDA evaluates non-DAC and DAC active moieties separately.
How it may work
Pituitary GHRH receptor/cAMP signaling stimulates GH release.8
Lack of verified human administration evidence
FDA's 2024 review did not identify human studies of CJC-1295 free base or acetate. The healthy-volunteer studies it found appeared to involve the DAC active moiety, with incompletely specified salt forms.
1No demonstrated treatment effectiveness for GHD
The FDA review found no human effectiveness studies for growth-hormone deficiency for any of the evaluated CJC forms.
1Research areas and evidence gaps
- Clinical effectiveness, pharmacokinetics, and long-term safety of the exact no-DAC product.
- Whether a supplier's name identifies the intended peptide and salt form.
- Validated effects on recovery, sleep, muscle gain, or aging.
Community reports Unvalidated
PepPedia describes growth-hormone, body-composition, and sleep use, commonly with another secretagogue.2
PepPedia's editorial protocol summary, not measured community consensus. Benefits, product identity, and safety are not independently verified; these reported practices are not recommendations. No matching human no-DAC study regimen was verified.
Search coverage and review status
No additional exact-form human study was verified. Retained the FDA review explaining why DAC results cannot validate no-DAC products.
- Checked
- 2026-10-12
- Search
- "CJC-1295" "without DAC" clinical study
- Catalog
- Pep-Pedia ↗ · 4 listed references retained
- Targeted search and selected primary-source checks, not an exhaustive systematic review.
- Preserved bibliography entries marked unreviewed have not had their findings independently verified.
AI-prepared summaries. Independent medical editorial review is pending.
References
Original sources and review status. Open a reference to read its summary.
1FDA briefing: CJC-1295 substances and DAC formsPrimary source checked
AI-PREPARED SUMMARY
Distinguishes active moieties, documents no-DAC evidence gaps, and records marketed powder amounts. The briefing is not an approval.
Lack of verified human administration evidence
FDA's 2024 review did not identify human studies of CJC-1295 free base or acetate. The healthy-volunteer studies it found appeared to involve the DAC active moiety, with incompletely specified salt forms.
No demonstrated treatment effectiveness for GHD
The FDA review found no human effectiveness studies for growth-hormone deficiency for any of the evaluated CJC forms.
2PepPedia: reported practices (accessed October 12, 2026)Community source checked
AI-PREPARED SUMMARY
Secondary editorial account of discussed practices; not a clinical trial or representative survey.
3Long-term Safety Profile of Modified GRF Analogs (2015)No study link suppliedPep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: The source claims no pituitary structural or functional abnormalities during six-month animal exposure; no original study link is supplied.
Reported population / model
Animal model
Reported study details
6 months · Daily administration
Pep-Pedia supplies no original study link for this card. Study identity, design, doses and result remain unverified. No study link supplied
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
4Comparative Analysis: CJC-1295 vs Native GHRH (2010)No study link suppliedPep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Fourfold receptor affinity and greater enzyme resistance are claimed for the no-DAC variant; the unlinked study cannot establish a clinical advantage.
Reported population / model
In vitro + Human
Reported study details
Various doses · Receptor binding assays
Pep-Pedia supplies no original study link for this card. Study identity, design, doses and result remain unverified. No study link supplied
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
5Growth Hormone Pulsatility with Mod GRF 1-29 (2008)No study link suppliedPep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: The source claims preserved GH pulses without desensitization in 24 people over 30 days; the underlying study is not linked.
Reported population / model
Human
Reported study details
100mcg 3x daily · 30 days · 24 subjects
Pep-Pedia supplies no original study link for this card. Study identity, design, doses and result remain unverified. No study link supplied
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
6Pharmacokinetics of Modified GRF(1-29) in Healthy Adults (2006)No study link suppliedPep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: The source reports a GH peak 15–30 minutes after injection in 12 people. A hormone-response peak is not an elimination half-life.
Reported population / model
Human
Reported study details
100-200mcg · Single dose · 12 subjects
Pep-Pedia supplies no original study link for this card. Study identity, design, doses and result remain unverified. No study link supplied
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
7Pep-Pedia: CJC-1295 (no DAC) — reported pharmacokineticsReference estimate; not independently verified human PKCommunity source checked
AI-PREPARED SUMMARY
Lists a half-life of 30 min and a peak time of 15 min. Stated attribution: Teichman et al. 2006. The cited Teichman study concerns CJC-1295 with DAC. It does not establish a 30-minute human half-life for the no-DAC form. Five half-lives is not complete clearance, and the source’s “cleared” value is not used as a measured endpoint.
Secondary reference page checked; the underlying quantitative claim is not independently confirmed. · Checked 2026-10-12
8Pep-Pedia: CJC-1295 (no DAC) — route-specific referenceReference page checked; underlying claims require separate verification.Community source checked
AI-PREPARED SUMMARY
Source page checked across available routes. Protocols, cycles, storage, mechanisms and pairing claims are secondary reports; checking the page does not independently validate those claims. Original concise summaries are used here.
Content coverage audit · Checked 2026-10-12